CSL Limited provided earnings guidance for the fiscal year 2022. CSL's net profit after tax for fiscal year 2022 is anticipated to be in the range of approximately $2.15 billion to $2.25 billion at constant currency. This includes approximately $90 million to $110 million in transaction costs related to the agreement to acquire Vifor Pharma.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
273.3 AUD | -1.85% | +0.70% | -4.66% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.66% | 87.53B | |
+1.32% | 40.42B | |
-19.27% | 29.48B | |
+57.86% | 25.43B | |
-17.69% | 11.49B | |
-43.00% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B | |
+2.29% | 7.67B |
- Stock Market
- Equities
- CSL Stock
- News CSL Limited
- CSL Limited Provides Earnings Guidance for the Fiscal Year 2022